|
|
Press Releases
| All Releases |
|---|
 |
Osiris Therapeutics Reports Third Quarter 2007 Financial Results
11-12-07
19.0 KB
|
| |
COLUMBIA, Md., Nov 12, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today its results for the third quarter ended September 30, 2007. For the quarter...
|
|
Osiris Announces Third Quarter 2007 Financial Results Conference Call
11-08-07
9.6 KB
|
| |
COLUMBIA, Md., Nov 08, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that it will report its financial results for the quarter ended September ...
|
|
Osiris Therapeutics to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
11-06-07
8.9 KB
|
| |
COLUMBIA, Md., Nov 06, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and CEO, is scheduled to present at...
|
|
Osiris Therapeutics Initiates Phase II Clinical Trial Evaluating Prochymal(TM) for Type 1 Diabetes
10-25-07
16.1 KB
|
| |
COLUMBIA, Md., Oct 25, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced the initiation of a Phase II clinical trial evaluating Prochymal, a stem cell therapy, as a treatment for type 1 diabetes. Through a partnership with the Juvenile Diabetes Research Foundation (JDRF), the organization has provided $4 million in fun...
|
|
Osiris Therapeutics Receives FDA Clearance to Initiate Phase III Pivotal Trial for Prochymal(TM) as a First Line Treatment for Acute Graft vs. Host Disease
10-17-07
15.8 KB
|
| |
COLUMBIA, Md., Oct 17, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced the initiation of a Phase III pivotal trial evaluating Prochymal as a first line agent in the treatment of acute Graft vs. Host Disease (GVHD), a life threatening complication of bone marrow transplantation that currently has no approved treatment.
...
|
|
Osiris Therapeutics Secures $30 Million Financing Commitment from Chairman and Largest Shareholder
10-09-07
11.8 KB
|
| |
COLUMBIA, Md., Oct 09, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (Nasdaq: OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that it has entered into a financing agreement for up to $30 million from...
|
|
Major Shareholders of Osiris Therapeutics Elect to Extend Lock-up Agreement
09-20-07
9.7 KB
|
| |
COLUMBIA, Md., Sep 20, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that Peter Friedli, Chairman of the Board of Directors of Osiris, and cert...
|
|
Osiris Therapeutics to Present at the ThinkEquity Partners' Fifth Annual Growth Conference
09-14-07
8.9 KB
|
| |
COLUMBIA, Md., Sep 14, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and CEO, is scheduled to present at...
|
|
Osiris Therapeutics to Present at the Thomas Weisel Partners Healthcare Conference 2007
08-31-07
8.9 KB
|
| |
COLUMBIA, Md., Aug 31, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company, announced today that C. Randal Mills, Ph.D., President and CEO, will present at the Thomas Weisel Partners Healthcare Conference in Boston. Dr. Mills is scheduled to present at 3:50 pm ET on September 5, 2007. A live audi...
|
|
Osiris Therapeutics Appoints Nuclear and Radiological Countermeasure Advisory Board
08-30-07
12.8 KB
|
| |
COLUMBIA, Md., Aug 30, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), announced the formation of a Nuclear and Radiological Countermeasure Advisory Board. The Advisory Board will provide guidance to the company on the development of Prochymal(TM) for use as a medical countermeasure for nuclear terrorism and other radiological emer...
|
|
|
 |
Stock Information
OSIR - (NASDAQ)
$6.57
+ 0.09
|
11-20-09
4:11 PM ET
Quotes delayed at least 20 minutes. Information provided by eSignal.
|
|
|
|
|
Shareholder Tools
|
|
